US4055660A - Treatment for warts - Google Patents
Treatment for warts Download PDFInfo
- Publication number
- US4055660A US4055660A US05/704,285 US70428576A US4055660A US 4055660 A US4055660 A US 4055660A US 70428576 A US70428576 A US 70428576A US 4055660 A US4055660 A US 4055660A
- Authority
- US
- United States
- Prior art keywords
- wart
- warts
- solution
- procaine
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title description 22
- 201000010153 skin papilloma Diseases 0.000 claims abstract description 143
- 208000000260 Warts Diseases 0.000 claims abstract description 135
- 239000000243 solution Substances 0.000 claims abstract description 54
- 238000002347 injection Methods 0.000 claims abstract description 39
- 239000007924 injection Substances 0.000 claims abstract description 39
- 229960004919 procaine Drugs 0.000 claims abstract description 36
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000005526 vasoconstrictor agent Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12
- 210000004247 hand Anatomy 0.000 description 11
- 239000007788 liquid Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 210000003811 finger Anatomy 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229960001309 procaine hydrochloride Drugs 0.000 description 3
- 229950003255 propoxycaine Drugs 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GEFQWZLICWMTKF-CDUCUWFYSA-N (-)-alpha-Methylnoradrenaline Chemical compound C[C@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 GEFQWZLICWMTKF-CDUCUWFYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000934136 Verruca Species 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 201000004303 plantar wart Diseases 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IIASWRRVNLXCCT-UHFFFAOYSA-N 1-[4-(butylamino)phenyl]-2-(dimethylamino)-2-hydroxypropan-1-one;hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)C(C)(O)N(C)C)C=C1 IIASWRRVNLXCCT-UHFFFAOYSA-N 0.000 description 1
- UUDLQDCYDSATCH-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;hydrate Chemical compound O.OC(=O)C(O)C(O)C(O)=O UUDLQDCYDSATCH-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- CHGHIVYMRGPMMY-UHFFFAOYSA-N 2-hydroxybenzoic acid;urea Chemical compound NC(N)=O.OC(=O)C1=CC=CC=C1O CHGHIVYMRGPMMY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000221785 Erysiphales Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000997826 Melanocetus johnsonii Species 0.000 description 1
- GEFQWZLICWMTKF-UHFFFAOYSA-N Nordephrine Chemical compound CC(N)C(O)C1=CC=C(O)C(O)=C1 GEFQWZLICWMTKF-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940045942 acetone sodium bisulfite Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
- 229940095758 cantharidin Drugs 0.000 description 1
- 229930008397 cantharidin Natural products 0.000 description 1
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229950008484 corbadrine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- -1 diethylaminoethyl ester Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000005224 forefinger Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229950009305 nordefrin Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229940068582 podophyllin Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000004935 right thumb Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 description 1
- VIMFRQPQNUFOEQ-UHFFFAOYSA-M sodium;hydrogen sulfate;propan-2-one Chemical compound [Na+].CC(C)=O.OS([O-])(=O)=O VIMFRQPQNUFOEQ-UHFFFAOYSA-M 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
Definitions
- Warts, or verrucae are a common and troublesome occurrence of viral etiology. Their epidemiology is not well understood. In many cases partial or complete remission occurs over a period of months or years, however many cases refuse to resolve spontaneously.
- Plantar warts so characterized because they are found on the sole of the foot, are particularly painful and stubborn, and are the subject of many cure efforts.
- the successful surgical removal of plantar warts with a blunt instrument is described in Archives of Dermatology, Vol 108, p 79, July, 1973.
- An interesting procedure for treating recalcitrant plantar warts by sensitization of the patient to dinitrochlorobenzene, followed by topical treatment of the wart with a dinitrochlorobenzene solution, is reported in Journal of the American Podiatry Association, Vol 63, No 7, p 293, July, 1973.
- warts include curretage, dessication, electric cutting, freezing with carbon dioxide or liquid nitrogen, and treatment with salicylic acid, podophyllin resin, formaldehyde, bichloracetic acid, silver nitrate, linseed oil, and cantharidin.
- warts Despite substantial effort, a satisfactory cure for warts has not been found. Although some of the treatments mentioned above are statistically quite effective, none are completely effective, and many are painful, dangerous and leave unaceptable scars. In addition, even after removal by these methods, warts frequently recur at original or new sites and must be retreated.
- Procaine is the diethylaminoethyl ester of para-aminobenzoic acid, and has the following formula: ##STR1##
- Sold under the trade names of Novocain, Ethocaine, and Neocaine a solution of the hydrochloride salt of procaine has been sold for many years as a local anesthetic, and has achieved wide use.
- Procaine is a white crystalline powder, slightly soluble in water, melting at about 60° C. The hydrochloride salt, however, is freely water-soluble.
- the solution is sold as a 2% solution of procaine in water, generally with a small amount of vasoconstrictor, with sufficient strong acid (usually HCl) added to reduce the solution pH to between 4 and 5.
- the salt procaine hydrocloride is formed at this pH, but readily dissociates at pH above 7.
- procaine has a long history of safe use, and is essentially systemically non-toxic, being readily hydrolyzed in the tissues and detoxified in the liver. Amounts to 20 cc of the 2% procaine solution are commonly used in dentistry without ill effects.
- procaine has been used in combination with other anesthetics, such as provocaine (2 diethylaminoethyl 4-aminopropoxylbenzonate) or tetracaine (p-butylaminobenzoyl-dimethylaminoethanol hydrochloride) for increased potency.
- provocaine diethylaminoethyl 4-aminopropoxylbenzonate
- tetracaine p-butylaminobenzoyl-dimethylaminoethanol hydrochloride
- procaine Although primarily known as an injected anesthetic, procaine has been reported to be useful for other related and non-related purposes. For example, McCrea, U.S. Pat. No. 2,105,197, issued Jan. 11, 1938, discloses the use of procaine as a topical anesthetic to reduce itching sensation. Dekker, U.S. Pat. No. 3,175,941, issued Mar. 30, 1965 shows procaine to be an active fungicide against powdery mildew on plants. Tulek, U.S. Pat. No. 2,539,848, issued Jan. 30, 1951 uses procaine as a raw material for the manufacture of procaine urea salicylate, useful in treating ulcers. In addition, recent newspaper articles have reported procaine-based drugs to be useful for anti-depressant and anti-aging activity in humans.
- Warts are resolved by subcutaneous injection of a procaine solution around the periphery of at least one wart. A few months after the injection, all of the warts on the infected body disappear.
- the first problem in treating warts according to the invention is to determine which wart or warts should be injected. Although selection of a single key wart does not seem to be critical, best results are obtained by working with the largest and ugliest, or "seed" wart, on the body. Only one wart need be treated according to the invention in order to establish the required reaction; if the treatment is effective for the treated wart, all of the other warts on the body will also be removed. More than one wart may be treated if desired; injection of multiple warts could increase the probability that the necessary initial sensitization reaction would occur.
- the procaine solution is then injected in the immediate vicinity of the wart.
- the immediate vicinity is meant directly around the periphery of the wart, or underneath the wart, or directly into the wart, or a combination of all of these locations.
- Injection is accomplished with a conventional syringe in multiple locations into and around the periphery of the wart, and directly into the wart.
- the injection needle is inserted subderminally just underneath the wart from several locations around the wart, such that the solution is infiltrated directly below the wart, between the wart tissue and the surrounding skin tissue.
- the wart raises up from the volume of solution injected, and the tissue beneath the wart turns white in color. Solution is also injected directly into the center of the wart.
- the wart be completely saturated with solution; the injection is made under considerable pressure, and should continue until solution spurts out from the wart. Injection into the wart must continue until part of the wart structure is physically destroyed and bleeding occurs. While the amount of the solution used may vary with the size of the wart to be treated, a suitable total amount is usually between 0.5 and 5.0 cc's of 2% procaine solution, preferably from 1 to 1.5 cc's. Larger amounts can be used especially for large animals, but are generally unnecessary; no problems with toxicity or side effects from the procaine solution would be expected with injections totaling less than 20 cc's at any one time. If the solution contains a vasoconstrictor, less than about 1.5 cc's of solution should be injected into any phalanx at one time to avoid shutting off blood circulation to the phalanx.
- procaine solutions containing a vasoconstrictor appear to resolve the warts more quickly than solutions not containing a vasoconstrictor.
- vasoconstrictor-containing solutions typically about two to four weeks after injection, the injected wart develops a redness and inflammation around its base. The redness may persist for anywhere from 5 to 20 days, and then subsides. The warts then change character to a dry and crusty appearance, and ultimately slough off in 2-4 months after the initial injection.
- treating solutions not containing a vasoconstrictor up to 6 months have been required for some cases.
- the initial injection may not induce the necessary reaction, in which case one or more additional injection attempts may be made in the same or a new site. It is noted that a second injection is most commonly required in persons with allergies.
- warts have an ability to effectively mask the existence of the causative virus from the normal body reactions. For this reason, the body does not generate the necessary antibodies and antigens to combat the virus.
- the injection of procaine appears to break down the ability of the wart virus to mask its presence from the body's normal immune reactions. This procedure would explain the redness at the base of the wart several weeks after injection, indicating the presence of sensitization, and would also explain the fact that all of the warts on the body are cured by a single injection site. This mechanism would also explain the fact that the warts are not known to return after treatment, indicating development of a permanent immunity to the causative virus.
- the solution used for injection preferably comprises procaine in the amount of from about 0.1% wt to about 10% wt, more preferably from 0.5-4% wt, in aqueous solution.
- the solution also preferably contains an effective amount of a vasoconstrictor, many of which are derivatives or analogs of phenylethylamine, such as epinephrine, levarterenol, arterenol, phenylephrine (Neo-Synephrin) or nordefrin (3,4 dihydroxy-phenylpropanolamine, levo- or racemic).
- a vasoconstrictor retards absorption of the procaine in the tissues, thus prolonging its molecular existence.
- Procaine which itself is a vasodilator, is easily and rapidly hydrolyzed to paraaminobenzoic acid and diethylaminoethanol in the tissues.
- concentration of vasoconstrictor must be sufficient to allow vasoconstriction activity, and will depend on the particular vasoconstrictor selected. Generally concentration between about 0.005 and about 0.5 milligrams per milliliter of solution are adequate. Selection of an appropriate concentration is well within the skill of the art, using the same criteria as is used in formulating anesthetic solutions; guidance may be found in Chapter Seven of Monheim, "Local Anesthesia and Pain Control in Dental Practice", published by the Mosby Company, 1957.
- the wart-treating solution may also contain additional components such as known local anesthetics such as propoxycaine hydrochloride and tetracaine hydrochloride, or other materials not harmful to the body, such as sodium chloride.
- known local anesthetics such as propoxycaine hydrochloride and tetracaine hydrochloride, or other materials not harmful to the body, such as sodium chloride.
- procaine is only slightly water-soluble, the active solution is best prepared from a water-soluble salt of procaine, especially a water-soluble acid salt such as the hydrochloride salt which is readily commercially available. These salts are readily water-soluble, and have a pH in solution of between 4 and 5. Any salt which is water-soluble and which decomposes in the tissues without harmful effects to the body may be used.
- procaine is used herein in connection with a solution, it is understood to include any solubilized form of procaine, including acid salts such as the hydrochloride.
- the patient a 42 year old caucasian, had a severe outbreak of warts on his hands and had been to dermatologists in several cities. At least 30 very large filiform warts existed. Prior treatments, including irradiation, were completely ineffective, and the patient indicated his job as a meat cutter to be in jeopardy because of the unattractive appearance of his hands.
- the patient had about 20 warts on his hands and fingers which had been present for several years.
- Approximately 3 cc's of Solution B was injected in and around the periphery of a wart on the first finger of the right hand.
- a different wart site, located on another finger was injected in a manner similar to the first injection.
- the second wart site was again injected with about 3 cc's of the solution.
- the warts had changed character and were raised and dry but had not fallen off.
- about half of the warts had fallen off, and after an additional 90 days, the remainder had disappeared. Only a slight lightness in pigment remained where the warts had been.
- a white male, age 14 had a severe wart growth on his left elbow and a plantar wart on his left foot. About 2 cc's of Solution B was injected peripherally under and into the wart on the elbow. Within three months, both the wart on his elbow and the plantar wart had fallen off.
- the treatment of the invention is useful on animals. Treatments identical to the treatment described herein have satisfactorily removed warts from dogs, and would be expected to be successful for any warm-blooded mammal having warts.
- Solution C a standard solution commercially available from Abbott Laboratories, used in all of the following Examples VI-XIX, is as follows:
- the patient a boy age 10, had moderate multiple warts on his hands which had been present for about 2 years.
- a single injection of a wart on the right hand resulted in complete resolution in about 6 months.
- the patient was a 12 year old female having severe warts which had been present for about 24 months on both hands and knees. Prior treatment with liquid nitrogen and electrosurgery had no positive effect. After injection of one wart, in accord with the invention, all warts completely resolved without scarring in 4 months.
- the patient a five year old boy, had severe warts on his hands, arms and face.
- the warts had been present for 24 months and had been treated with liquid nitrogen and with a 2% salicylic acid in vergo cream without success.
- a single wart on the left hand was injected in accord with the invention. All warts on the body resolved within 6 months of treatment.
- the patient a 37 year old male, had a single plantar verruca on his left sole. Prior treatment with 40% salicylic acid plasters was ineffective. The lesion had been present for about 36 months. A single injection of 2% procaine intralesionally resolved the wart within 6 months.
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
______________________________________
SOLUTION A
Compound % wt
______________________________________
procaine hydrochloride 2
propoxycaine hydrochloride
0.4
levo-nordefrin 0.005
sodium chloride 0.3
acetone sodium bisulfate
less than 0.2
water balance
______________________________________
SOLUTION B
Compound % wt
______________________________________
procaine hydrochloride 2.0
propoxycaine hydrochloride
0.4
levarterenol (as bitartrate monohydrate)
0.0033
sodium chloride 0.3
acetone sodium bisulfite
less than 0.2
water balance
______________________________________
______________________________________
SOLUTION C
Compound % wt
______________________________________
procaine hydrochloride, USP
2.0
sodium bisulfite 0.1
water balance
______________________________________
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/704,285 US4055660A (en) | 1974-06-26 | 1976-07-12 | Treatment for warts |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48368174A | 1974-06-26 | 1974-06-26 | |
| US05/704,285 US4055660A (en) | 1974-06-26 | 1976-07-12 | Treatment for warts |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US48368174A Continuation-In-Part | 1974-06-26 | 1974-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4055660A true US4055660A (en) | 1977-10-25 |
Family
ID=27047738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/704,285 Expired - Lifetime US4055660A (en) | 1974-06-26 | 1976-07-12 | Treatment for warts |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US4055660A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808576A (en) * | 1986-04-28 | 1989-02-28 | Mobay Corporation | Remote administration of hyaluronic acid to mammals |
| US5151415A (en) * | 1991-05-23 | 1992-09-29 | Dallas Sirany | Method of treating a papova-type viral infection |
| WO1994023748A1 (en) * | 1993-04-08 | 1994-10-27 | The University Of Queensland | Administration of vaso-active agent and therapeutic agent |
| US5433950A (en) * | 1990-05-07 | 1995-07-18 | Schering-Plough Healthcare Products, Inc. | Flexible collodion compositions |
| US6020005A (en) * | 1999-04-08 | 2000-02-01 | Weathers; Ervin G. | Genital wart treatment |
| US20120189718A1 (en) * | 2009-08-24 | 2012-07-26 | Kuok Leong Tam | Medicine for dissolving and eliminating wart and excrescence consisting of protein and its uses |
| US8859794B2 (en) | 2005-04-26 | 2014-10-14 | Battelle Memorial Institute | Use of fatty acids as feed material in polyol process |
| US8877952B2 (en) | 2005-04-26 | 2014-11-04 | Battelle Memorial Institute | Pre-esterification of primary polyols to improve solubility in solvents used in the polyol process |
-
1976
- 1976-07-12 US US05/704,285 patent/US4055660A/en not_active Expired - Lifetime
Non-Patent Citations (5)
| Title |
|---|
| Goodman et al., 3rd Edition, Pharmacological Basis of Therapeutics, pp. 378-385, (1965). * |
| Sadik, Handbook of Non-Prescription Drugs, (1973), pp. 180-183. * |
| The Merck Manual, (1972), 12th Edition, pp. 1436-1438. * |
| The Merck Manual, 10th Edition, pp. 1444-1446. * |
| wilson, et al., Textbook of Organic Medicinal and Pharmaceutical Chemistry, 4th Edition, (1962), pp. 520-522. * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808576A (en) * | 1986-04-28 | 1989-02-28 | Mobay Corporation | Remote administration of hyaluronic acid to mammals |
| US5433950A (en) * | 1990-05-07 | 1995-07-18 | Schering-Plough Healthcare Products, Inc. | Flexible collodion compositions |
| US5151415A (en) * | 1991-05-23 | 1992-09-29 | Dallas Sirany | Method of treating a papova-type viral infection |
| WO1994023748A1 (en) * | 1993-04-08 | 1994-10-27 | The University Of Queensland | Administration of vaso-active agent and therapeutic agent |
| US5750141A (en) * | 1993-04-08 | 1998-05-12 | The University Of Queensland | Administration of vaso-active agent and therapeutic agent |
| US6020005A (en) * | 1999-04-08 | 2000-02-01 | Weathers; Ervin G. | Genital wart treatment |
| US8859794B2 (en) | 2005-04-26 | 2014-10-14 | Battelle Memorial Institute | Use of fatty acids as feed material in polyol process |
| US8877952B2 (en) | 2005-04-26 | 2014-11-04 | Battelle Memorial Institute | Pre-esterification of primary polyols to improve solubility in solvents used in the polyol process |
| US20120189718A1 (en) * | 2009-08-24 | 2012-07-26 | Kuok Leong Tam | Medicine for dissolving and eliminating wart and excrescence consisting of protein and its uses |
| US10251925B2 (en) * | 2009-08-24 | 2019-04-09 | Kuok Leong Tam | Pharmaceutical composition for dissolving and eliminating pathological tissues and pathogens and its usage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4016264A (en) | Wart treatment with phosphonoacetic acid or derivatives thereof | |
| Dünser et al. | Critical care management of major hydrofluoric acid burns: a case report, review of the literature, and recommendations for therapy | |
| US4055660A (en) | Treatment for warts | |
| Henry et al. | Intravenous regional calcium gluconate perfusion for hydrofluoric acid burns | |
| US4469702A (en) | Analgesic composition and use thereof to ameliorate deep and intractable pain | |
| Van Der Velden et al. | Dermatography with bleomycin as a new treatment for verrucae vulgaris | |
| EP1143966B1 (en) | Preparation for warts | |
| WO2010079513A2 (en) | Painless treatment of warts, corns & callus | |
| HUT69724A (en) | Therapeutic method by using caesium ions | |
| Ward | Warts and granuloma annulare | |
| CA1215323A (en) | Curative composition for buerger's disease | |
| O'Connor | Surgery plus freezing as a technique for treating pilonidal disease | |
| Kaplan | The allantoin treatment of ulcers | |
| CN108635362A (en) | A kind of pharmaceutical composition for treating diabetes | |
| Williams | Small wounds and localised infections | |
| Shumacker Jr et al. | STUDIES IN EXPERIMENTAL FROSTBITE. | |
| Shumacker JR et al. | Studies in Experimental Frostbite: VI. Effect of Rutin and Benadryl With Some Notes on Plaster Casts and the Role of Edema | |
| Milowsky et al. | The Use of Ether to Abolish Arrhythmia During Cyclopropane Anesthesia: A Case Report | |
| LEONARD | Progressive gangrene in an operative wound | |
| US2760901A (en) | Method for removing verrucae | |
| Luxenburger | Clinical and Experimental Use of Orthoform | |
| Kaplan et al. | The local injection of Penicillin in acute circumscribed infections | |
| Apfelberg | Adjunctive considerations for laser resurfacing | |
| Gaiger | Glanders in man: A second attack after apparent recovery | |
| Cornbleet | Use of intravenously given hydroxyzine for simple pain-producing office procedures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: INSTITUTE FOR SOCIAL AND SCIENTIFIC DEVELOPMENT TH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SOLOMON, JACK D.;REEL/FRAME:004610/0320 Effective date: 19860827 Owner name: INSTITUTE FOR SOCIAL AND SCIENTIFIC DEVELOPMENT TH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOLOMON, JACK D.;REEL/FRAME:004610/0320 Effective date: 19860827 |
|
| AS | Assignment |
Owner name: SOLOMON, JACK D. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:GAMING AND TECHNOLOGY, INC., A CORP. OF NV;REEL/FRAME:005004/0788 Effective date: 19880906 Owner name: SOLOMON, JACK D. Free format text: AGREEMENT,;ASSIGNOR:GAMING AND TECHNOLOGY, INC.;REEL/FRAME:004961/0002 Effective date: 19851216 Owner name: SOLOMON, JACK D. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:GAMING AND TECHNOLOGY, INC.;REEL/FRAME:004961/0028 Effective date: 19870824 |